Company profile
Homepage - Iceni Glycoscience
Iceni Glycoscience Limited is a UK company with status active founded in 2014 based in East of England.
Updated 06 Jun 2026 16:52
Financial period: 1 Apr 2024 to 31 Mar 2025
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
Development of diagnostics of both human and animal viruses.
Iceni Glycoscience develops carbohydrate-based therapeutics and point-of-care diagnostics for infectious diseases using their own research in glycoscience, nanoparticle technology, and bioconjugation chemistry.
Company founded in March 2014. First contract secured September 2014.
Too early
1 Jul 2023 to 31 Dec 2023
Nature produces a range of carbohydrate polymers -- e.g. starch, cellulose, chitin -- which have important properties that support a wide range of biological structures and processes. These materials are also widely exploited across market sectors -- thickeners in processed food; tableting agents; absorbent materials in sanitary products; wound dressings;...
1 Jan 2021 to 31 Dec 2022
In any infectious disease outbreak, the rapid triage of potential carriers of infection is essential to control the spread of infection and to allocate resources efficiently. Iceni Diagnostics is repurposing the technology most famously used in the home pregnancy test kit to create a new generation of rapid, point-of-care diagnostics. These studies are be...
1 May 2020 to 28 Feb 2021
In any infectious disease outbreak, the rapid triage of potential carriers of infection is essential to control the spread of infection and to allocate resources efficiently. We will repurpose the technology, most famously used in the pregnancy test, to create a new diagnostic to rapidly identify coronavirus carriers. This approach requires no infrastruct...
1 Jan 2017 to 31 Dec 2017
ICENI Diagnostics provides point of care (POC) diagnostics and carbohydrate-based therapeutics, with a focus in infectious disease. A single device, dual assay human viruses, the subject of this proposal, has its basis in synthetic biology and is dependent on the assembly of recognition ligands using enzymatic production processes.. The developed assay us...
